Flow diverter retreatment for intracranial aneurysms: A meta-analysis of efficacy and feasibility

• Published in: Interventional Neuroradiology 2024-02, Vol.30 (1), p.37-42
• Main Authors: Lee, Irene (Tai-Lin), Kao, Yung-Shuo, Lai, Yen-Jun, Yen, Ho-Hsian
• Format: Article
• Language: English
• Subjects: Embolization, Therapeutic - methods; Endovascular Procedures - methods; Feasibility Studies; Humans; Intracranial Aneurysm - diagnostic imaging; Intracranial Aneurysm - etiology; Intracranial Aneurysm - therapy; Retreatment; Retrospective Studies; Stents - adverse effects; Treatment Outcome
• ISSN: 1591-0199; 2385-2011
• DOI: 10.1177/15910199221095972

Background Recurrent intracranial aneurysm carries a risk of rupture and retreatment is often necessary. However, there is no consensus on the best retreatment modality of choice. Flow diverter has emerged as a promising option for this population in recent years. Given its high cost, patient selection to optimize outcomes is very important. Purpose To identify patient factors predisposing to failure of flow diverter retreatment. Method We conducted a systematic search on PubMed, Cochrane Library, Embase, Ovid/Medline, and ClinicalTrial.gov from 2000 to 2021. Studies regarding flow diverter retreatment of recurrent aneurysms were analyzed if they meet the inclusion criteria. Results A total of twenty-six studies were identified. Among 374 patients retreated with flow diverters, about 0.86 [0.81; 0.92] were successfully occluded and only 0.06 [0.02; 0.10] had unfavorable neurological outcomes. Major complications included intracranial hemorrhage (n = 7), ischemic stroke or thromboembolic event (n = 12), and death (n = 2). In-stent stenosis was reported in 10 of the cases. Saccular aneurysms are associated with a higher occlusion rate while aneurysm location, size, status, and prior treatment modality have no significant impact on retreatment efficacy. Conclusions We demonstrated that flow diverter is an effective retreatment strategy except in patients with non-saccular aneurysms. It should be considered as a first-line option for patients with recurrent intracranial aneurysm.